HCPCS Level II code J9294 represents a 10 mg injectable formulation of pemetrexed (Hospira) specifically designated as not therapeutically equivalent to J9305. This code is used to bill for the medication product itself when administered as an antineoplastic agent, typically in hospital outpatient infusion centers or oncology clinics. Nationally, accurate coding of specific drug formulations matters for correct billing, inventory tracking, and payer adjudication, especially when therapeutically non-equivalent products are distinguished.

Key payers commonly included in analyses of this code are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for pemetrexed administration, typical sites of service, and the implications of a non-therapeutic-equivalence designation. The publication also summarizes what to expect in payer coverage patterns, common modifier usage (listed separately), and relevant coding considerations. Where available, benchmarks and policy updates affecting HCPCS drug coding and reimbursement practices are outlined. Data not provided in the input are noted as unavailable and are omitted from the summary.